Melanomas with NF1 mutations may not respond to MEK inhibitors (although neurofibromatosis is responsive) because melanomas tend to have important co-alterations, whereas neurofibromatosis is driven only by NF1 alterations [191, 192]. Here, NF1 is linked to melanoma.